Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 9732154 Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia

Patent 9732154 was granted and assigned to Janssen Biotech on August, 2017 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Patent Applicant

Janssen Biotech

Current Assignee

Janssen Biotech

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

97321540

Patent Inventor Names

Parul Doshi0

Date of Patent

August 15, 2017

Patent Application Number

146299650

Date Filed

February 24, 2015

Patent Citations Received

‌

US Patent 11713355 Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia

‌

US Patent 12091466 Anti-CD38 antibodies for treatment of light chain amyloidosis and other CD38-positive hematological malignancies

‌

US Patent 12060432 Combination therapies with anti-CD38 antibodies

‌

US Patent 11708420 Subcutaneous formulations of anti-CD38 antibodies and their uses

‌

US Patent 11708419 Subcutaneous formulations of anti-CD38 antibodies and their uses

Patent Primary Examiner

‌

Sheela J. Huff

Patent abstract

The present invention relates to combination therapies with anti-CD38 antibodies.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 9732154 Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API